Antitumor agent.
It is a non-steroidal aromatase inhibitor – an enzyme that participates in the synthesis of estrogen in postmenopausal women.
Aromatase promotes the conversion of androgens synthesized in the adrenal glands (primarily androstenedione and testosterone) into estrone and estradiol.
The inhibition of aromatase activity is realized by competitive binding to a subunit of this enzyme – cytochrome P450 heme, which leads to decrease of estrogen biosynthesis in all tissues, including in tissues of estrogen-dependent tumors.
Indications
The treatment of malignant breast tumors in women in the period of natural or artificially induced menopause after therapy with anti-estrogenic drugs.
Active ingredient
Composition
1 tablet:
Active substance:
2.5 mg letrozole.
Associates:
Magnesium aluminosilicate 10 mg,
croscarmellose sodium 3 mg,
colloidal silicon dioxide 3 mg,
magnesium stearate 0.5 mg,
ludipress 81 mg.
Composition of the film coating:
Opadray II Yellow 85F32733 (polyvinyl alcohol 35-49%, talc 9.8-25%, macrogol 3350 7.35-35.2%, titanium dioxide and iron oxide yellow 15.15-30%).
How to take, the dosage
The dose is 2.5 mg once daily.
The treatment is continued during the period of disease progression.
Special Instructions
In patients with a CKG of less than 10 ml/min, the safety of letrozole has not been studied, so if it is necessary to use it in these cases, the balance between the expected therapeutic effect and possible risks of treatment should be carefully weighed.
The effects of letrozole may decrease the ability to concentrate and the speed of psychomotor reactions, so it is recommended to avoid driving and other potentially dangerous activities during treatment.
Contraindications
Endocrine status characteristic of the premenopausal period; pregnancy, lactation, hypersensitivity to letrozole.
Side effects
Possible: headache, nausea, peripheral edema, general weakness, hot flashes, thinning hair, skin rash, vomiting, dyspepsia, weight gain, muscular-skeletal pain, anorexia, vaginal bleeding, leukorrhea, constipation, dizziness, increased appetite, increased sweating.
Rarely: shortness of breath, thrombophlebitis, bloody discharge from the vagina.
Similarities
Weight | 0.014 kg |
---|---|
Shelf life | 2 years. |
Conditions of storage | In a dry, light-protected place at a temperature not exceeding 25 °C. |
Manufacturer | Pharmstandard-Leksredstva, Russia |
Medication form | pills |
Brand | Pharmstandard-Leksredstva |
Related products
Buy Estrolet, 2,5mg 30 pcs. with delivery to USA, UK, Europe and over 120 other countries.